<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143581">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231633</url>
  </required_header>
  <id_info>
    <org_study_id>IST CRVO 1118147</org_study_id>
    <nct_id>NCT01231633</nct_id>
  </id_info>
  <brief_title>Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)</brief_title>
  <official_title>Comparative Study of Initial Ozurdex (Dexamethasone Implant) Versus Avastin (Bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Long Island Vitreoretinal Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Long Island Vitreoretinal Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare visual improvement and total number of intraocular
      injections in eyes with macular edema following central retinal vein occlusion (CRVO)after
      initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in visual acuity (number of ETDRS letters), at Month 6 as compared with baseline in each treatment arm</measure>
    <time_frame>Baseline - Month 6</time_frame>
    <description>The change in visual acuity (number of ETDRS letters), at Month 6 as compared with baseline in each treatment arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The total number of additional Avastin injections following initial treatment in each treatment arm</measure>
    <time_frame>Baseline - Month 6</time_frame>
    <description>Total Number of addiitonal Avastin injections during study- From baseline to Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of macular edema, as measured by ocular coherence tomography (OCT) and fluorescein angiography</measure>
    <time_frame>Baseline - Month 6</time_frame>
    <description>Presence of macular edema, as measured by ocular coherence tomography (OCT) and fluorescein angiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Macular Edema</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Ozurdex, 0.7mg dexamethasone</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Dexamethasone implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Avastin, bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of central retinal vein occlusion (CRVO)

          -  Age 18 years or older

          -  ETDRS Visual acuity between 3 and 72 letters and approximate Snellen equivalent of
             20/40 to 20/800

          -  OCT Central foveal thickness &gt;250 microns

          -  Negative pregnancy test for women of childbearing potential

          -  Ability to provide written informed consent

          -  Capable of complying with study protocol

        Exclusion Criteria:

          -  History of glaucoma in the study eye with intraocular pressure &gt;21mmHg on more than
             one topical medication. Combination drugs are considered more than one medication

          -  History of steroid-related glaucoma (steroid response)

          -  Previous intraocular injection of steroid medication within 90 days

          -  Avastin (bevacizumab) or Lucentis (ranibizumab) within 60 days

          -  Evidence of significant retinal ischemia on fluorescein angiography in the opinion of
             the treating physician

          -  Previous intraocular surgery (e.g. Cataract Surgery) with in 60 days

          -  Concurrent ocular disease that would limit visual acuity in the opinion of the
             treating physician

          -  Dense cataract that precludes clinical examination and retinal imaging of the retina

          -  History of allergy to dexamethasone, bevacizumab, betadine

          -  Ocular or systemic conditions that may pose a threat to the health of the subject in
             the opinion of the treating physician

          -  Unwilling or unable to follow or comply with all study related procedures

          -  Current participation in another clinical medical investigation or trial or has
             received any investigational drug within 12 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent A Deramo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Island Vitreoretinal Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Vitreous Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Riverhead</city>
        <state>New York</state>
        <zip>11901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 30, 2015</lastchanged_date>
  <firstreceived_date>October 28, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Long Island Vitreoretinal Consultants</investigator_affiliation>
    <investigator_full_name>Vincent. A. Deramo, M.D.</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Central Retinal Vein Occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
